NCI has selected Exact Sciences Corp.’s testing laboratory in Phoenix, AZ to participate in the ComboMATCH clinical trials, an NCI-funded precision medicine initiative. As a ComboMATCH-designated lab, Exact Sciences will use its new OncoExTra test to analyze tumor tissue and paired normal blood samples from patient participants and uncover the specific abnormalities in a patient’s tumor that may be most effective to treat.
As of the end of August, NCI has selected 1,891 competing awards for funding this fiscal year, all of which will be funded by the year’s end, NCI Director Anthony G. Letai said to the National Cancer Advisory Board.
